华东医药GLP-1类双靶点新药,信达生物双抗1类新药获批临床

医药经济报
24 Feb

华东医药GLP-1类双靶点新药再获批两项临床今日,中国国家药监局药品审评中心(CDE)官网最新公示,华东医药1类新药HDM1005注射液获得两项新的临床试验默示许可,拟开发用于阻塞性睡眠呼吸暂停(OSA)合并肥胖或超重成人患者的治疗。公开资料显示,HDM1005是华东医药在研的一款多肽类GLP-1受体和GIP受体的双靶点激动剂,此前已经在中国和美国获得过多项IND。OSA是因为在睡眠过程中气道阻塞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10